Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1984 1
1986 1
1988 1
1989 1
1990 1
1993 2
1994 1
1995 1
1996 1
1998 3
1999 2
2000 3
2001 7
2002 5
2003 4
2004 13
2005 8
2006 17
2007 13
2008 19
2009 22
2010 18
2011 26
2012 28
2013 20
2014 26
2015 30
2016 46
2017 37
2018 43
2019 51
2020 39
2021 56
2022 66
2023 50
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

609 results

Results by year

Filters applied: . Clear all
Page 1
Breast cancer treatment: A phased approach to implementation.
Mutebi M, Anderson BO, Duggan C, Adebamowo C, Agarwal G, Ali Z, Bird P, Bourque JM, DeBoer R, Gebrim LH, Masetti R, Masood S, Menon M, Nakigudde G, Ng'ang'a A, Niyonzima N, Rositch AF, Unger-Saldaña K, Villarreal-Garza C, Dvaladze A, El Saghir NS, Gralow JR, Eniu A. Mutebi M, et al. Cancer. 2020 May 15;126 Suppl 10:2365-2378. doi: 10.1002/cncr.32910. Cancer. 2020. PMID: 32348571 Free article. Review.
This is followed by strengthening the patient pathway, with consideration given to a dynamic balance between centralization of services into centers of excellence to achieve better quality and decentralization of services to increase patient access. ...
This is followed by strengthening the patient pathway, with consideration given to a dynamic balance between centralization of servic …
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA, Syed YY, Keam SJ. Heo YA, et al. Drugs. 2019 May;79(7):767-777. doi: 10.1007/s40265-019-01120-1. Drugs. 2019. PMID: 31030380 Free PMC article. Review.
Pegaspargase treatment in patients with relapsed ALL and hypersensitivity to E. coliL-asparaginase had a similar tolerability profile to that observed in patients with newly diagnosed ALL. Given the potentially reduced immunogenicity and more convenient dosage regimen over …
Pegaspargase treatment in patients with relapsed ALL and hypersensitivity to E. coliL-asparaginase had a similar tolerability profile to tha …
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Chua BH, et al. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Lancet. 2022. PMID: 35934006 Clinical Trial.
FINDINGS: Between June 25, 2007, and June 30, 2014, 1608 patients were randomly assigned to have no boost (805 patients) or boost (803 patients). Conventional WBI was given to 831 patients, and hypofractionated WBI was given to 777 patients. ...FUNDING: National Hea …
FINDINGS: Between June 25, 2007, and June 30, 2014, 1608 patients were randomly assigned to have no boost (805 patients) or boost (803 patie …
Once and Only Once.
Gasser S. Gasser S. Cell. 2019 Apr 18;177(3):495-498. doi: 10.1016/j.cell.2019.03.034. Epub 2019 Apr 2. Cell. 2019. PMID: 30952443 Free article. Review.
The 2019 Gairdner Prize will be given to John F.X. Diffley and Bruce Stillman for their groundbreaking work on the mechanisms and control of the initiation of eukaryotic DNA replication. ...
The 2019 Gairdner Prize will be given to John F.X. Diffley and Bruce Stillman for their groundbreaking work on the mechanisms and con …
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies.
Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, Grunstein RR, Hoyos CM. Suraev AS, et al. Sleep Med Rev. 2020 Oct;53:101339. doi: 10.1016/j.smrv.2020.101339. Epub 2020 May 16. Sleep Med Rev. 2020. PMID: 32603954
Results indicated that there is insufficient evidence to support routine clinical use of cannabinoid therapies for the treatment of any sleep disorder given the lack of published research and the moderate-to-high risk of bias identified within the majority of preclinical a …
Results indicated that there is insufficient evidence to support routine clinical use of cannabinoid therapies for the treatment of any slee …
Comprehensive Evaluation for Chronic Pain.
Fidler SK. Fidler SK. Prim Care. 2022 Sep;49(3):375-385. doi: 10.1016/j.pop.2022.02.001. Epub 2022 Aug 29. Prim Care. 2022. PMID: 36153080 Review.
Through thorough patient interview, physical examination, diagnostics, and standardized assessment tools, primary care clinicians can create a robust care plan for patients with chronic pain. Given the multifaceted nature of chronic pain, it is a diagnosis that fits into c …
Through thorough patient interview, physical examination, diagnostics, and standardized assessment tools, primary care clinicians can create …
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. Kitko CL, et al. J Clin Oncol. 2023 Apr 1;41(10):1864-1875. doi: 10.1200/JCO.22.00958. Epub 2022 Dec 2. J Clin Oncol. 2023. PMID: 36459673 Free PMC article. Clinical Trial.
RESULTS: Forty enrolled patients (17 phI; 23 phII) received at least one axatilimab dose. In phI, a dose of 3 mg/kg given once every 4 weeks met the optimal biologic dose definition. Two dose-limiting toxicities occurred at the 3 mg/kg dose given once every 2 weeks. …
RESULTS: Forty enrolled patients (17 phI; 23 phII) received at least one axatilimab dose. In phI, a dose of 3 mg/kg given once every …
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey.
Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I, Kasparek T, Frade S, Barrio SF, Augustin M. Armstrong AW, et al. Dermatology. 2023;239(4):621-634. doi: 10.1159/000528945. Epub 2023 Apr 19. Dermatology. 2023. PMID: 37075723 Free PMC article.
METHODS: Psoriasis and Beyond was a cross-sectional, quantitative online survey conducted in patients with a self-reported, physician-given diagnosis of moderate to severe psoriasis (body surface area [BSA] >5% to <10%, affecting sensitive and/or prominent bo …
METHODS: Psoriasis and Beyond was a cross-sectional, quantitative online survey conducted in patients with a self-reported, physician-giv …
Corrections.
[No authors listed] [No authors listed] Science. 1994 May 27;264(5163):1350. doi: 10.1126/science.264.5163.1350-a. Science. 1994. PMID: 17780856
In "Women in Science: Some Books of the Year" (11 March, p. 1458) the name of the senior editor of second edition of The History of Women and Science, Health, and Technology should have been given as Phyllis Holman Weisbard, and the name of the editor of the first edition …
In "Women in Science: Some Books of the Year" (11 March, p. 1458) the name of the senior editor of second edition of The History of Women an …
Seizure documentation in people living with epilepsy.
Goldstein J, Kwon CS, Harmon M, Buchhalter J, Kukla A, McCallum S, Raman L, Herman ST, Fureman B, Jette N. Goldstein J, et al. Epilepsy Behav. 2021 Dec;125:108383. doi: 10.1016/j.yebeh.2021.108383. Epub 2021 Oct 31. Epilepsy Behav. 2021. PMID: 34731718 Review.
In order for these tools to be utilized most effectively, patient input must be central to their development. Given the limitations of seizure documentation, the development of accurate, non-invasive seizure detection devices is crucial for accurate seizure monitoring....
In order for these tools to be utilized most effectively, patient input must be central to their development. Given the limitations o …
609 results